<DOC>
	<DOCNO>NCT00470223</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Zoledronic acid may stop growth tumor cell bone . Giving chemotherapy without zoledronic acid surgery may make tumor small reduce amount normal tissue need remove . Giving treatment surgery may kill tumor cell remain surgery . It yet know whether give combination chemotherapy together zoledronic acid effective combination chemotherapy alone treat osteosarcoma . PURPOSE : This randomized phase III trial study combination chemotherapy zoledronic acid see well work compare combination chemotherapy alone treat patient osteosarcoma .</brief_summary>
	<brief_title>Combined Chemotherapy With Without Zoledronic Acid Patients With Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient osteosarcoma treat combination chemotherapy without zoledronic acid . Secondary - Compare overall survival patient treat regimen . - Compare percentage patient good histologic response . - Compare long short term toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( &lt; 18 year vs 18-25 year vs &gt; 25 year ) , risk group ( nonmetastatic resectable v metastatic unresectable ) , treatment center . Patients receive either methotrexate-based chemotherapy doxorubicin hydrochloride-based chemotherapy accord age . - Methotrexate-based chemotherapy ( patient ≤ 25 year age ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive methotrexate IV week 1-3 , 7 , 8 , 12 , 13 etoposide IV ifosfamide IV week 4 9 . - Arm II : Patients receive methotrexate , etoposide , ifosfamide arm I . Patients also receive zoledronic acid IV week 1 , 5 , 9 , 13 . All patient undergo surgery week 14 . After surgery , patient assign 1 2 group treatment , base histological response . - Good responder ( &lt; 10 % viable cell ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive methotrexate IV week 1-3 , 7-9 , 13-15 , 19-21 etoposide IV week 4 10 . Patients also receive ifosfamide IV week 4 , 10 , 16 . - Arm II : Patients receive methotrexate , etoposide , ifosfamide arm I . Patients also receive zoledronic acid IV week 3 , 7 , 11 , 15 , 19 , 23 . - Bad responder ( &gt; 10 % viable cell ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive methotrexate IV week 1 , 5 , 9 , 13 , 17 doxorubicin hydrochloride IV cisplatin IV week 2 , 6 , 10 , 14 , 18 . - Arm II : Patients receive methotrexate , doxorubicin hydrochloride , cisplatin arm I . Patients also receive zoledronic acid IV arm II ( good responder ) . - Doxorubicin hydrochloride-based chemotherapy ( patient ≥ 18 year age ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin hydrochloride IV ifosfamide hydrochloride IV week 1 , 4 , 7 , 10 , 13 cisplatin IV week 1 , 7 , 13 . - Arm II : Patients receive doxorubicin hydrochloride , ifosfamide , cisplatin arm I . Patients also receive zoledronic acid IV week 1 , 5 , 9 , 13 . All patient undergo surgery week 16 . After surgery , patient assign 1 2 group treatment , base histological response . - Good responder ( &lt; 10 % viable cell ) : Patients randomize 1 2 treatment arm . - Arm I : Patients receive doxorubicin hydrochloride IV week 1 7 ifosfamide IV week 1 , 4 , 7 , 10 . - Arm II : Patients receive doxorubicin hydrochloride ifosfamide arm I . Patients also receive zoledronic acid IV week 1 , 5 , 9 , 13 , 17 , 21 . - Bad responder ( &gt; 10 % viable cell ) : - Arm I : Patients receive etoposide IV ifosfamide IV week 1 , 4 , 7 , 10 , 13 . - Arm II : Patients receive etoposide ifosfamide arm I . Patients also receive zoledronic acid arm II ( good responder ) . PROJECTED ACCRUAL : A total 440 patient accrue study .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Criteria Histologically confirm highgrade osteosarcoma Bilirubin ≤ 2 time upper limit normal No medical condition would preclude study treatment Not pregnant nursing Fertile patient must use effective contraception Shortening fraction ≥ 28 % LVEF ≥ 50 % Glomerular filtration rate ≥ 70mL/min No recent dental problem , include infection , traumatization , surgery Exclusion Criteria Lowgrade osteosarcoma Small cell osteosarcoma Maxillary osteosarcoma Primary resect osteosarcoma Osteosarcoma multiple metastasis complete removal feasible even shrinkage chemotherapy Extraosseous osteosarcoma Any prior osteonecrosis maxilla No prior chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
</DOC>